



ArQule, Inc. to Present at BMO Capital Markets 10th Annual Focus on Healthcare Conference

WOBURN, Mass., Jul 30, 2010 (BUSINESS WIRE) -- ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the BMO Capital Markets 10th Annual Focus on Healthcare Conference on August 5, 2010 at 9:30 a.m.

The presentation will be web cast live and may be accessed through the investor relations section of the Company's website, <http://www.arqule.com>. The BMO conference will be held at the Sheraton New York Hotel and Towers, New York City.

About ArQule

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule's lead product, in Phase 2 clinical development, is ARQ 197, an inhibitor of the c-Met receptor tyrosine kinase. The Company is also conducting Phase 1 clinical testing with ARQ 621, designed to inhibit the Eg5 kinesin motor protein. The Company's pre-clinical pipeline includes a compound designed to inhibit the B-RAF kinase. ArQule's current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP(TM)), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase. These include a series of small molecule inhibitors of fibroblast growth factor receptor (FGFR).

SOURCE: ArQule, Inc.

ArQule, Inc.
William B. Boni, 781-994-0300
VP, Investor Relations/
Corp. Communications
www.ArQule.com

Copyright Business Wire 2010